Even though we have a large patient population, the proportion of glioblastoma patients harboring the IDH mutation of all glioblastoma patients is only 1.7%, which is less than described in the literature, which is about 5%.27 This may be a possible limitation that none of the glioblastoma patients harboring the IDH mutation showed the T2/FLAIR-mismatch sign. The gene discussed is IDH1; the disease is glioblastoma.